| Ident. | Authors (with country if any) | Title |
|---|
| 000028 (2013) |
Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France] | Trial designs used to study neuroprotective therapy in Parkinson's disease |
| 000081 (2013) |
Alex A. Macdonald [Canada] ; Oury Monchi [Canada] ; Ken N. Seergobin [Canada] ; Hooman Ganjavi [Canada] ; Ruzbeh Tamjeedi [Canada] ; Penny A. Macdonald [Canada] | Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function |
| 000205 (2012) |
Anthony E. Lang [Canada] ; Jose A. Obeso [Espagne] | Stem cell therapy for Parkinson's disease |
| 000493 (2010) |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew J. Lees [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
| 000595 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
| 000639 (2010) |
A. Jon Stoessl [Canada] | Continuous dopaminergic therapy in Parkinson disease: Time to stride back? |
| 000729 (2009) |
Seung U. Kim [Canada, Corée du Sud] ; Jean De Vellis [États-Unis] | Stem cell‐based cell therapy in neurological diseases: A review |
| 000763 (2009) |
Mohamed A. Shaker [Canada] ; Husam M. Younes [Canada, Qatar] | Interleukin‐2: Evaluation of routes of administration and current delivery systems in cancer therapy |
| 000764 (2009) |
William Weiner [États-Unis] ; Eric Ahlskog [États-Unis] ; Stewart Factor [États-Unis] ; Oksana Suchowersky [Canada] ; Stephen Reich [États-Unis] | Initiating therapy in Parkinson's disease |
| 000824 (2009) |
Peter J. Trainer [Royaume-Uni] ; Shereen Ezzat [Canada] ; Gwyn A. D Ouza [Royaume-Uni] ; Gary Layton [Royaume-Uni] ; Christian J. Strasburger [Allemagne] | A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly |
| 000874 (2008) |
Manho Kim ; Soon-Tae Lee ; Kon Chu ; Seung U. Kim [Canada] | Stem cell‐based cell therapy for Huntington disease: A review |
| 000966 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
| 000A05 (2007) |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
| 000B67 (2006) |
Zheng Huang [États-Unis] ; Masoom A. Haider [Canada] ; Susan Kraft [États-Unis] ; Qun Chen [États-Unis] ; Dominique Blanc [France] ; Brian C. Wilson [Canada] ; Fred W. Hetzel [États-Unis] | Magnetic resonance imaging correlated with the histopathological effect of Pd‐bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland |
| 000C04 (2006) |
Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis] | Crossroads in GDNF therapy for Parkinson's disease |
| 000C12 (2006) |
John P. Etminan [Canada] ; John P. Gill [Canada] ; John P. Fitzgerald [Canada] ; John P. Samii [États-Unis] | Challenges and Opportunities for Pharmacoepidemiology in Drug‐Therapy Decision Making |
| 000F86 (2001) |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study |
| 001081 (2001) |
Gerlinde A. S. Metz ; Tracy Farr ; Mark Ballermann ; Ian Q. Whishaw | Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6‐OHDA dopamine‐depleted (hemi‐Parkinson analogue) rats |
| 001162 (2000) |
C. J. D. Ross [Canada] ; M. Ralph [Canada] ; P. L. Chang [Canada] | Somatic Gene Therapy for a Neurodegenerative Disease Using Microencapsulated Recombinant Cells |
| 001261 (2000) |
K. W. Marshall [Canada] ; V. Manolopoulos [Canada] ; K. Mancer [Canada] ; J. Staples [Canada] ; A. Damyanovich [Canada] | Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis |
| 001702 (1997) |
Magdy Basta [Canada] ; Magdy Mbbch [Canada] ; George J. Klein [Canada] ; Raymond Yee [Canada] ; Andrew Krahn [Canada] ; John Lee [Canada] | CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA |
